KCI·KMQ has established an anti infection research and service platform with dual qualifications of BSL2 and ABSL2. The BSL-2 laboratory covers an area of approximately 200m ² and includes cells, viruses, and bacteria; The experimental area of ABSL2 is about 1000m ², including 300m ² for small animal laboratory and 700m ² for large animal laboratory. This platform is equipped with a professional operation and technical team, including senior scientists, dedicated laboratory personnel, dedicated veterinarians, and a QA management system. The staff have received special training in professional operations, obtained relevant qualifications, and carried out related work under the guidance and management of scientists with experience in anti infection research and development.
After nearly 2 years of internal research and development and external services, this platform has completed the filing of more than 70 pathogenic microorganisms, successfully established more than 20 animal models of viral and bacterial fungal infections, and has cooperated with more than 20 new drug research and development enterprises in the fields of human vaccines and anti infective drugs, animal vaccines and anti infective drugs, etc., to assist in the development and application of preclinical drugs. At present, the main businesses involved include:
Human vaccines and anti infective drugs, veterinary vaccines and anti infective drugs
（1）In vitro anti infective efficacy test:
Antiviral activity - EC50/CC50 detection; MIC drug sensitivity test; FIC measurement; Effects of biological characteristics, etc.
（2）Immunogenicity testing of vaccines in vivo: neutralization test, hemagglutination inhibition test, cellular immunity test, etc;
（3）Animal protective testing against viruses: vaccines, antiviral drugs;
（4）Infectious animal testing.
